Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valoctocogene roxaparvovec in Hemophilia A with Inhibitors
NCT04684940Phase 2Completed
- Sponsor
- BioMarin Pharmaceutical
- Start
- Dec 2020
- Primary completion
- Apr 2026
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 7
01
Overview
A Phase 2 trial of valoctocogene roxaparvovec in hemophilia A, sponsored by BioMarin Pharmaceutical. Started Dec 2020; status: completed.
02
Drugs
valoctocogene roxaparvovec
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT04684940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04684940.